Literature DB >> 20403097

Functional variation in the arginine vasopressin 2 receptor as a modifier of human plasma von Willebrand factor levels.

A Y Nossent1, J H Robben, P M T Deen, H L Vos, F R Rosendaal, C J M Doggen, J L Hansen, S P Sheikh, R M Bertina, J C J Eikenboom.   

Abstract

SUMMARY
OBJECTIVES: Stimulation of arginine vasopressin 2 receptor (V2R) with arginine vasopressin (AVP) results in a rise in von Willebrand factor (VWF) and factor VIII plasma levels. We hypothesized that gain-of-function variations in the V2R gene (AVPR2) would lead to higher plasma levels of VWF and FVIII. METHODS AND
RESULTS: We genotyped the control populations of two population-based studies for four AVPR2 variations: a-245c, G12E, L309L, and S331S. Rare alleles of a-245c, G12E, and S331S, which were in linkage disequilibrium, were associated with higher VWF propeptide, VWF and FVIII levels. The functionality of the G12E variant was studied in stably transfected MDCKII cells, expressing constructs of either 12G-V2R or 12E-V2R. Both V2R variants were fully glycosylated and expressed on the basolateral membrane. The binding affinity of V2R for AVP was increased three-fold in 12E-V2R-green fluorescent protein (GFP) cells, which is in accordance with increased levels of VWF propeptide associated with the 12E variant. The dissociation constant (K(D)) was 4.5 nm [95% confidence interval (CI) 3.6-5.4] for 12E-V2R-GFP and 16.5 nm (95% CI 10.1-22.9) for 12G-V2R-GFP. AVP-induced cAMP generation was enhanced in 12E-V2R-GFP cells.
CONCLUSIONS: The 12E-V2R variant has increased binding affinity for AVP, resulting in increased signal transduction, and is associated with increased levels of VWF propeptide, VWF, and FVIII.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20403097     DOI: 10.1111/j.1538-7836.2010.03884.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

Review 1.  Congenital nephrogenic diabetes insipidus: the current state of affairs.

Authors:  Daniel Wesche; Peter M T Deen; Nine V A M Knoers
Journal:  Pediatr Nephrol       Date:  2012-03-17       Impact factor: 3.714

Review 2.  Functional architecture of Weibel-Palade bodies.

Authors:  Karine M Valentijn; J Evan Sadler; Jack A Valentijn; Jan Voorberg; Jeroen Eikenboom
Journal:  Blood       Date:  2011-01-25       Impact factor: 22.113

Review 3.  Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.

Authors:  Hanne B Moeller; Søren Rittig; Robert A Fenton
Journal:  Endocr Rev       Date:  2013-01-29       Impact factor: 19.871

4.  Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association.

Authors:  Karl C Desch; Ayse B Ozel; David Siemieniak; Yossi Kalish; Jordan A Shavit; Courtney D Thornburg; Anjali A Sharathkumar; Caitlin P McHugh; Cathy C Laurie; Andrew Crenshaw; Daniel B Mirel; Yoonhee Kim; Cheryl D Cropp; Anne M Molloy; Peadar N Kirke; Joan E Bailey-Wilson; Alexander F Wilson; James L Mills; John M Scott; Lawrence C Brody; Jun Z Li; David Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

Review 5.  Genetic regulation of plasma von Willebrand factor levels in health and disease.

Authors:  L L Swystun; D Lillicrap
Journal:  J Thromb Haemost       Date:  2018-10-30       Impact factor: 5.824

Review 6.  Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.

Authors:  Serena Milano; Monica Carmosino; Andrea Gerbino; Maria Svelto; Giuseppe Procino
Journal:  Int J Mol Sci       Date:  2017-11-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.